Comparing single and repeated dosimetry data for perfluorooctane sulfonate in rats

Toxicology Letters

Volumn 181, Issue 3, 2008, Pages 148-156

  Harris, Leona A ^a   Barton, Hugh A ^b  

^a The College of New Jersey   (United States)

^b U S ENVIRONMENTAL PROTECTION AGENCY   (United States)

Author keywords

PBPK; Perfluorooctane sulfonate; Pharmacokinetic modeling

Indexed keywords

PERFLUOROOCTANESULFONIC ACID;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD ANALYSIS; CONCENTRATION (PARAMETERS); CONCENTRATION RESPONSE; CONTROLLED STUDY; DATA BASE; DIET; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DOSIMETRY; DRUG EXPOSURE; FEMALE; HYDROPHOBICITY; KIDNEY CLEARANCE; KINETICS; LIVER CLEARANCE; MALE; MATHEMATICAL MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; RAT;

ADMINISTRATION, ORAL; AGING; ALKANESULFONIC ACIDS; ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENVIRONMENTAL POLLUTANTS; FEMALE; FLUOROCARBONS; INJECTIONS, INTRAVENOUS; MALE; MODELS, BIOLOGICAL; PREDICTIVE VALUE OF TESTS; RATS; REPRODUCIBILITY OF RESULTS; TIME FACTORS; TISSUE DISTRIBUTION;

ANIMALIA; RATTUS; RODENTIA;

EID: 52049117378     PISSN: 03784274     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxlet.2008.07.014     Document Type: Article

References (38)

1. 3M Company, 2001. 104-Week dietary chronic toxicity study with perfluorooctane sulfonic acid potassium salt (PFOS T-6295) in rats. 3M Study Report, Covance Study No.: 6329-183. Analytical laboratory report on determination of the presence and concentration of perfluorooctanesulfonate (PFOS) in the serum of Sprague-Dawley rats exposed to potassium perfluorooctanesulfonate via gavage. 3M Report No. Fact Tox-002, LRN-U2121.
2. 3M Company, 2002. 104-Week dietary chronic toxicity and carcinogenicity study with perfluorooctane sulfonic acid potassium salt (PFOS; T-6295) in rats. Final Report. 3M Company, St. Paul, MN. January 2, 2002. U.S. EPA Docket AR-226-1051a.
3. Alexander B.H., and Olsen G.W. Bladder cancer in perfluorooctanesulfonyl fluoride manufacturing workers. Ann. Epidemiol. 17 (2007) 471-478
4. Andersen M.E., Clewell III H.J., Tan Y.M., Butenhoff J.L., and Olsen G.W. Pharmacokinetic modeling of saturable, renal resorption of perfluoroalkylacids in monkeys-probing the determinants of long plasma half-lives. Toxicology 227 (2006) 156-164
5. Brown R.P., Delp M.D., Lindstedt S.L., Rhomberg L.R., and Beliles R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13 (1997) 407-484
6. Calafat A.M., Wong L.Y., Kuklenyik Z., Reidy J.A., and Needham L.L. Polyfluoroalkyl chemicals in the U.S. population: data from the National Health and Nutrition Examination Survey (NHANES) 2003-2004 and comparisons with NHANES 1999-2000. Environ. Health Perspect. 115 (2007) 1596-1602
7. Charles River Laboratories, 2008. Weight Chart for the Crl:CD(SD) Rat. http://www.criver.com/research_models_and_services/research_models/CD_IGS.html.
8. Ehresman D.J., Froehlich J.W., Olsen G.W., Chang S.C., and Butenhoff J.L. Comparison of human whole blood, plasma, and serum matrices for the determination of perfluorooctanesulfonate (PFOS), perfluorooctanoate (PFOA), and other fluorochemicals. Environ. Res. 103 (2007) 176-184
9. Fei C., McLaughlin J.K., Tarone R.E., and Olsen J. Fetal growth indicators and perfluorinated chemicals: a study in the Danish National Birth Cohort. Am. J. Epidemiol. 168 (2008) 66-72
10. Gerlowski L.E., and Jain R.K. Physiologically based pharmacokinetic modeling: principles and applications. J. Pharm. Sci. 72 (1983) 1103-1127
11. Giesy J.P., and Kannan K. Global distribution of perfluorooctane sulfonate in wildlife. Environ. Sci. Technol. 35 (2001) 1339-1342
12. Johnson, J.D., Gibson, S.J., Ober, R.F., 1979a. Extent and route of excretion and tissue distribution of total carbon-14 in rats after a single intravenous dose of FC-95-14C. Project No. 8900310200, Riker Laboratories, Inc., St. Paul, MN. U.S. EPA Docket AR-226-0006.
13. Johnson, J.D., Gibson, S.J., Ober, R.F., 1979b. Absorption of FC-95-14C in rats after a single oral dose. Project No. 8900310200, Riker Laboratories, Inc., St. Paul, MN. U.S. EPA Docket AR-226-0007.
14. Johnson J.D., Gibson S.J., and Ober R.F. Cholestyramine-enhanced fecal elimination of carbon-14 in rats after the administration of ammonium[14C] perfluorooctanoate or potassium [14C] perfluorooctanesulfonate. Fund. Appl. Toxicol. 4 (1984) 972-976
15. Jones P.D., Hu W., De Coen W., Newsted J.L., and Giesy J.P. Binding of perfluorinated fatty acids to serum proteins. Environ. Toxicol. Chem. 22 (2003) 2639-2649
16. Khor S.P., and Mayersohn M. Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling: residual tissue blood. I. Theoretical considerations. Drug Metab. Dispos. 19 (1991) 478-485
17. Krishnan K., and Andersen M.E. Physiologically based pharmacokinetic modeling in toxicology. In: Hayes A.W. (Ed). Principles and Methods in Toxicology. 3rd ed. (1994), Raven Press, Ltd., New York 149-188
18. Kudo N., and Kawashima Y. Toxicity and toxicokinetics of perfluorooctanoic acid in humans and animals. J. Toxicol. Sci. 28 (2003) 49-57
19. Lam G., Chen M., and Chiou W.L. Determination of tissue to blood partition coefficients in physiologically-based pharmacokinetic studies. J. Pharm. Sci. 71 (1982) 454-456
20. Lau C., Butenhoff J.L., and Rogers J.M. The developmental toxicity of perfluoroalkyl acids and their derivatives. Toxicol. Appl. Pharmacol. 198 (2004) 231-241
21. Lau C., Anitole K., Hodes C., Lai D., Pfahles-Hutchens A., and Seed J. Perfluoroalkyl acids: a review of monitoring and toxicological findings. Toxicol. Sci. 99 (2007) 366-394
22. Mendel C.M. The free hormone hypothesis: distinction from the free hormone transport hypothesis. J. Androl. 13 (1992) 107-116
23. Nestorov I. Whole body pharmacokinetic models. Clin. Pharmacokinet. 42 (2003) 883-908
24. OECD, 2002. Co-Operation on Existing Chemicals: Hazard Assessment of Perfluorooctane Sulfonate (PFOS) and Its Salts. Joint Meeting of the Chemicals Committee and the Working Party of Chemicals, Pesticides and Biotechnology, Organisation for Economic Cooperation and Development.
25. Olsen G.W., Huang H.Y., Helzlsouer K.J., Hansen K.J., Butenhoff J.L., and Mandel J.H. Historical comparison of perfluorooctanesulfonate, perfluorooctanoate, and other fluorochemicals in human blood. Environ. Health Perspect. 113 (2005) 539-545
26. Olsen G.W., Burris J.M., Ehresman D.J., Froehlich J.W., Seacat A.M., Butenhoff J.L., and Zobel L.R. Half-life of serum elimination of perfluorooctanesulfonate, perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workers. Environ. Health Perspect. 115 (2007) 1298-1305
27. Olsen G.W., Mair D.C., Church T.R., Ellefson M.E., Reagen W.K., Boyd T.M., Herron R.M., Medhdizadehkashi Z., Nobiletti J.B., Rios J.A., Butenhoff J.L., and Zobel L.R. Decline in perfluorooctanesulfonate and other polyfluoroalkyl chemicals in American Red Cross Adult Blood Donors, 2000-2006. Environ. Sci. Technol. 42 (2008) 4989-4995
28. PubChem, 2008. http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=3736298.
29. Seacat A.M., Thomford P.J., Hansen K.J., Olsen G.W., Case M.T., and Butenhoff J.L. Subchronic toxicity studies on perfluorooctanesulfonate potassium salt in cynomolgus monkeys. Toxicol. Sci. 68 (2002) 249-264
30. Seacat A.M., Thomford P.J., Hansen K.J., Clemen L.A., Eldridge S.R., Elcombe C.R., and Butenhoff J.L. Sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats. Toxicology 183 (2003) 117-131
31. Seacat A.M., Thomford P.J., Hansen K.J., Clemen L.A., Eldridge S.R., Elcombe C.R., and Butenhoff J.L. Erratum to "sub-chronic dietary toxicity of potassium perfluorooctanesulfonate in rats". Toxicology 192 (2003) 263-264
32. Seshagiri P.B., and Adiga P.R. Comparison of biotin binding protein of pregnant rat serum with rat serum albumin. J. Biosci. 14 (1989) 221-231
33. Tan Y.M., Clewell III H.J., and Andersen M.E. Time dependencies in perfluorooctylacids disposition in rat and monkeys: a kinetic analysis. Toxicol. Lett. 177 (2008) 38-47
34. Teeguarden J.G., and Barton H.A. Computational modeling of serum-binding proteins and clearance in extrapolations across life stages and species for endocrine active compounds. Risk Anal. 24 (2004) 751-770
35. Trudel D., Horowitz L., Wormuth M., Scheringer M., Cousins I.T., and Hungerbühler K. Estimating consumer exposure to PFOS and PFOA. Risk Anal. 28 (2008) 251-269
36. Wambaugh, J.F., Barton, H.A., Setzer, R.W., submitted for publication. Comparing models for PFOA pharmacokinetics Using Bayesian analysis. J. Pharmacokinet. Pharmacodyn.
37. Washburn S.T., Bingman T.S., Braithwaite S.K., Buck R.C., Buxton L.W., Clewell H.J., Haroun L.A., Kester J.E., Rickard R.W., and Shipp A.M. Exposure assessment and risk characterization for perfluorooctanoate in selected consumer articles. Environ. Sci. Technol. 39 (2005) 3904-3910
38. Yuan J. Modeling blood/plasma concentrations in dosed feed and dosed drinking water toxicology studies. Toxicol. Appl. Pharmacol. 119 (1993) 131-141